Fig. 1From: Tocilizumab in chronic active antibody-mediated rejection: rationale and protocol of an in-progress randomized controlled open-label multi-center trial (INTERCEPT study)Flow chart of the Intercept-study. DSA donor-specific antibodies, eGFR estimated glomerular filtration rate, KTx kidney transplant, m months, mGFR measured glomerular filtration rate, MPA mycophenolic acid, sc subcutaneous, SOC standard of care, UACR urine albumin:creatinine ratioBack to article page